Barrow Hanley Mewhinney & Strauss LLC Sells 1,844,022 Shares of Smith & Nephew plc (NYSE:SNN)

Barrow Hanley Mewhinney & Strauss LLC decreased its position in Smith & Nephew plc (NYSE:SNN - Free Report) by 46.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 2,104,505 shares of the medical equipment provider's stock after selling 1,844,022 shares during the period. Barrow Hanley Mewhinney & Strauss LLC owned about 0.48% of Smith & Nephew worth $51,729,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its holdings in shares of Smith & Nephew by 4.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,120 shares of the medical equipment provider's stock valued at $224,000 after purchasing an additional 399 shares in the last quarter. National Bank of Canada FI raised its position in Smith & Nephew by 36.5% during the fourth quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock valued at $41,000 after buying an additional 446 shares during the period. Bleakley Financial Group LLC raised its position in Smith & Nephew by 3.5% during the fourth quarter. Bleakley Financial Group LLC now owns 17,704 shares of the medical equipment provider's stock valued at $435,000 after buying an additional 596 shares during the period. Signaturefd LLC lifted its stake in Smith & Nephew by 4.3% in the 4th quarter. Signaturefd LLC now owns 15,772 shares of the medical equipment provider's stock worth $388,000 after acquiring an additional 653 shares in the last quarter. Finally, Principal Securities Inc. boosted its position in Smith & Nephew by 87.6% during the 4th quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock worth $36,000 after acquiring an additional 691 shares during the period. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on SNN shares. Wall Street Zen upgraded shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a report on Wednesday, February 26th. HSBC lowered shares of Smith & Nephew from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Hsbc Global Res downgraded shares of Smith & Nephew from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. UBS Group lowered Smith & Nephew from a "buy" rating to a "neutral" rating in a report on Wednesday, March 12th. Finally, Canaccord Genuity Group lifted their price objective on Smith & Nephew from $27.00 to $28.00 and gave the company a "hold" rating in a research report on Thursday, May 1st. Six equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $28.00.

Smith & Nephew Stock Performance

SNN stock traded down $0.24 during midday trading on Wednesday, hitting $28.69. 156,614 shares of the company traded hands, compared to its average volume of 794,896. Smith & Nephew plc has a twelve month low of $23.69 and a twelve month high of $31.72. The stock has a market capitalization of $12.56 billion, a price-to-earnings ratio of 13.27, a price-to-earnings-growth ratio of 1.26 and a beta of 0.68. The company has a quick ratio of 1.11, a current ratio of 2.51 and a debt-to-equity ratio of 0.63. The business has a 50 day simple moving average of $27.45 and a 200-day simple moving average of $26.45.

About Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.